Trial Profile
NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Etanercept (Primary)
- Indications Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Focus Therapeutic Use
- Acronyms NATIENS
- 23 Mar 2023 Status changed from not yet recruiting to recruiting.
- 15 Feb 2023 Planned End Date changed from 1 Aug 2027 to 1 Aug 2028.
- 15 Feb 2023 Planned primary completion date changed from 1 Aug 2026 to 1 Aug 2027.